New tuberculosis vaccines study findings reported from University of North Carolina
2007 OCT 22 -- Current study results from the report, 'Poly (lactide-co-glycolide) microspheres in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen 85B,' have been published. According to a study from the United States, "' To investigate the use of poly (lactide-co-glycolide) (PLGA) microparticles in respirable sizes as carriers for Antigen 85B (Ag85B), a secreted protein of Mycobacterium tuberculosis, with the ultimate goal of employing them in pulmonary delivery of tuberculosis vaccine. Recombinant Ag85B was expressed from two Escherichia coli strains and encapsulated by spray-drying in PLGA microspheres with/without adjuvants. These microspheres containing rAg85B were assessed for their ability to deliver antigen to macrophages for subsequent processing and presentation to the specific CD4 T-hybridoma cells DB-1." "DB-1 cells recognize the Ag85B(97-112) epitope presented in the context of MHC class II and secrete IL-2 as the cytokine marker. Microspheres suitable for aerosol delivery to the lungs (3.4-4.3 microm median diameter) and targeting alveolar macrophages were manufactured. THP-1 macrophage-like cells exposed with PLGA-rAg85B microspheres induced the DB-1 cells to produce IL-2 at a level that was two orders of magnitude larger than the response elicited by soluble rAg85B. This formulation demonstrated extended epitope presentation. PLGA microspheres in respirable sizes were effective in delivering rAg85B in an immunologically relevant manner to macrophages," wrote D. Lu and colleagues, University of North Carolina. The researchers concluded: "These results are a foundation for further investigation into the potential use of PLGA particles for delivery of vaccines to prevent M. tuberculosis infection." Lu and colleagues published the results of their research in Pharmaceutical Research (Poly (lactide-co-glycolide) microspheres in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen 85B. Pharmaceutical Research, 2007;24(10):1834-43). For additional information, contact D. Lu, University of North Carolina at Chapel Hill, Molecular Pharmaceutics, School of Pharmacy, Chapel Hill, North Carolina 27599-7360 USA.. The publisher of the journal Pharmaceutical Research can be contacted at: Kluwer Academic, Plenum Publ, 233 Spring St., New York, NY 10013, USA. Keywords: United States, Chapel Hill, Tuberculosis Vaccines, Biotechnology, Microparticle, Mycobacteria, Mycobacterium Tuberculosis, Nanotechnology, Pharmaceuticals, Vaccines. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via NewsRx.com.
|
